Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether selective COX‐2 inhibitors changes proportion of participants experiencing adverse events compared with non‐selective NSAIDs (very low certainty).